Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Cash & Equivalents data on file, last reported at $586.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 46.09% year-over-year to $586.4 million; the trailing twelve-month figure through Mar 2026 stood at $586.4 million (down 46.09% YoY), and the FY2025 full-year result was $618.7 million, down 33.4% from the prior year.
• Cash & Equivalents declined to $586.4 million in Q1 2026, from $618.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.2 billion in Q2 2023 to a low of $477.0 million in Q4 2023.
• A 5-year average of $1.2 billion and a median of $950.1 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 152.75% in 2022 and tumbled 72.12% in 2023, its largest moves.
• Tracing RPRX's Cash & Equivalents over 5 years: stood at $1.7 billion in 2022, then plunged by 72.12% to $477.0 million in 2023, then surged by 94.76% to $929.0 million in 2024, then sank by 33.4% to $618.7 million in 2025, then declined by 5.22% to $586.4 million in 2026.
• Business Quant data shows RPRX's Cash & Equivalents at $586.4 million in Q1 2026, $618.7 million in Q4 2025, and $938.9 million in Q3 2025.